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Abstract
Background: Lamina-associated polypeptides 2 (LAP2) is a nuclear protein that connects the nuclear lamina with chromatin.
Although its critical roles in genetic disorders and hematopoietic malignancies have been described, its expression and roles
in digestive tract cancers have been poorly characterized.
Methods: To examine the expression of LAP2 in patient tissues, we performed immunohistochemistry and real-time PCR. To
examine motility of cancer cells, we employed Boyden chamber, wound healing and Matrigel invasion assays. To reveal its
roles in metastasis in vivo, we used a liver metastasis xenograft model. To investigate the underlying mechanism, a cDNA
microarray was conducted.
Results: Immunohistochemistry in patient tissues showed widespread expression of LAP2 in diverse digestive tract cancers
including stomach, pancreas, liver, and bile duct cancers. Real-time PCR confirmed that LAP2b is over-expressed in gastric
cancer tissues. Knockdown of LAP2b did not affect proliferation of most digestive tract cancer cells except pancreatic cancer
cells. However, knockdown of LAP2b decreased motility of all tested cancer cells. Moreover, overexpression of LAP2b
increased motility of gastric and pancreatic cancer cells. In the liver metastasis xenograft model, LAP2b increased metastatic
efficacy of gastric cancer cells and mortality in tested mice. cDNA microarrays showed the possibility that myristoylated
alanine-rich C kinase substrate (MARCKS) and interleukin6 (IL6) may mediate LAP2b-regulated motility of cancer cells.
Conclusions: From the above results, we conclude that LAP2 is widely overexpressed in diverse digestive tract cancers and
LAP2b regulates motility of cancer cells and suggest that LAP2b may have utility for diagnostics and therapeutics in
digestive tract cancers.
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Introduction
Metastasis of cancer cells greatly affects prognosis of cancer
patients. Survival rate of patients who have distant metastasis is
significantly lower than those who have localized tumor in most
types of cancer [1]. One of critical factors in metastasis is
motility of cancer cells [2]. Many critical molecules which
regulate motility of cancer cells have been identified. Because
inhibition of migration is effective in treating metastasis in many
aspects, many migration inhibitors are under the clinical
development [3]. For example, Rho kinase is a small GTPase
which regulates actin and microtubulin network and cellular
protrusions. So, an inhibitor which targets Rho kinase is under
the clinical development [3].
Lamina-associated polypeptides 2 (LAP2) is one of LEM-
domain proteins which are inner nuclear membrane proteins
which share a common motif of approximately 40 amino acids,
known as the LEM-domain [4,5]. LEM-domain proteins connect
the inner nuclear membrane and the nuclear lamina with
chromatin through the barrier-to-autointegration factor (BAF).
The family of LEM-domain proteins includes LAP2 [6,7,8],
emerin [9], MAN1 [4], LEM2 [10] and LEM3 [11]. The name
LEM derives from LAP2, Emerin and MAN1 [4].
In addition to their structural roles in nuclear membrane, LEM-
domain proteins have been shown to play critical roles in various
cellular processes such as DNA replication and regulation of gene
expression. LAP2b regulates DNA replication by interacting with
HA95 during the G1 phase of the cell cycle [12]. This interaction
with HA95 leads the prereplication complexes to the replication
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of the prereplication complex components and triggers the
proteolysis of Cdc6.
Pathological consequences have been described for LEM-
domain proteins in genetic disorders in humans and are
collectively called laminopathies [5,13]. For example, Emerin
deficiency causes Emery-Dreifuss Muscular Dystrophy (EDMD)
[9,14,15] and MAN1 deficiency leads to osteopoikilosis, Buschke-
Ollendorf syndrome and melorheostosis [16]. In addition to these
laminopathies, involvement of LAP2 in carcinogenesis has been
described. For example, LAP2b has been shown to be involved in
proliferation of malignant lymphocytes [12,17,18]. Moreover,
overexpression of LAP2a was reported in larynx, lung, stomach,
breast and colon cancer tissues [19].
The LAP2 family of LEM domain proteins, is composed of at
least six isoforms in mammals: a, b, c, d, e, f, [6,20,21,22]. These
isoforms are generated by alternative splicing of the same
transcript. All isoforms except the mammalian LAP2a and LAP2f
are inner nuclear membrane proteins and share a similar domain
organization. The N-terminal segment contains the LEM-domain
and LEM-like domain. Unlike the LEM-domain, LEM-like
domain can interact directly with chromatin without help of
BAF. The C-terminal segment of LAP2 proteins has lamin-
binding domains. Notably the C-terminal segment of a-isoform
lacks a putative transmembrane domain, so the protein is
distributed throughout the nucleus. Although LAP2a, b, and c
are expressed ubiquitously in the majority of mammalian cells,
differential expression of LAP2 isoforms has been described.
Differentiated tissues highly express the LAP2c isoform, however,
tissues with proliferating cells express more of the LAP2a and
LAP2b isoforms [23].
Although its critical roles in genetic disorders and hematopoietic
malignancies have been described, expression and roles of LAP2
in other cells or diseases are poorly characterized. In the present
study, we found for the first time a novel role of LAP2b in
regulation of motility of cancer cells and overexpression of LAP2
in diverse digestive tract cancers.
Methods
Cell Cultures and Transfection
Following digestive tract cancer cells were used; gastric cancer
cells (SNU216, SNU638), cholangiocarcinoma cells (SNU1079,
HuCCT1), pancreatic cancer cells (PANC1, MIA-PACA2),
hepatocarcinoma cells (Huh7, HepG2). HuCCT1, HepG2,
SNU216, SNU638, SNU1079 and Huh7 cells were cultured in
RPMI1640 supplemented with 10% fetal bovine serum (FBS) and
100 mg/ml of penicillin/streptomycin. PANC1 and MIA-PACA2
cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DME)/high glucose supplemented with 10% FBS and 100 mg/ml
of penicillin/streptomycin. Most cells were cultured at 37uC, 5%
CO2 incubator. Cells were transfected with siRNA using
DhamaFECT Reagent 3 (Dhamacon, Lafayette, CO, USA)
according to the manufacturer’s instructions. The sequences of
siRNA are as follows: LAP2b siRNA (Bioneer, Daejeon, Korea),
59- ACA AGA GGG UCA AGA AGA A(dTdT) 239 and 59-
UUC UUC UUG ACC CUC UUG U(dTdT) 239; scrambled
(SCR) siRNA (Dhamacon, Lafayette, CO, USA), 59- GAU CCG
CAA AAG AGC GAA A(dTdT) 239 and 59- UUU CGC UCU
UUU CGC GAU C(dTdT) 239.
Overexpression of LAP2b
The DNA expression construct pCMV-SPORT6-LAP2b
(Thermo scientific open biosystem, Huntsville, AL, USA) was
used to drive overexpression and G418 (Sigma-Aldrich, St. Louis,
MO, USA) was used for selection. Cells were co-transfected with
pCMV-SPORT6-LAP2b/pIRES-Neo at a 5:2 ratio using Fu-
GENE HD (Roche, Nutley, NJ), in accordance with the
manufacturer’s instructions. MOCK cells were established simul-
taneously using empty control vector.
Western Blotting
After gel electrophoresis and transfer to a PVDF membrane,
the membrane was blocked for one hr. After adding primary
antibodies (mouse anti-human LAP2b (BD Biosciences, San
Jose, CA, USA, 1:1000) and mouse anti-a-tubulin (BioGenex,
1:10000)) in blocking solution the membrane was incubated in
the primary antibody at 4uC overnight on a shaker. The
appropriate secondary antibody was applied (1:2000, horserad-
ish peroxidase-conjugated anti-mouse) and incubated at room
temperature for 2 h on a shaker. Lastly, the proteins were
detected using LAS3000.
Real-time PCR
Gastric cancer tissues were obtained with written informed
consent from patients who underwent surgical resection at Pusan
National University Hospital and Pusan National University
Yangsan Hospital, and the study was approved by the institutional
review board of the hospitals (Permit Number 2009-13). Total
RNA from tissues or cells were extracted using Trizol reagent
(Invitrogen, Calsbad, CA, USA) or RNeasy Mini kit (Qiagen,
Valencia, CA, USA) in accordance with the manufacturer’s
protocol. cDNA was synthesized with MMLV reverse transcrip-
tase (Promega, Madison, WI, USA), dNTP and oligo-dT primers.
The primer sequences were as follows: LAP2b,5 9- AGG GCA
GAG CAA AGA CTC CAG TAA CAA 239 and 59- TTA TTC
CAG CTT GAG AAT AGC TCT GAT TGT GC 239;
MARCKS, 59- GTG CCC AGT TCT CCA AGA CCG CA
239 and 59- GGC CAT TCT CCT GTC CGT TCG CT 239,
IL6; 59- TAG CCG CCC CAC ACA GAC AGC C 239 and 59-
TTC TGC CAG TGC CTC TTT GCT GCT 239; STAT3, 59-
AAC ATG GCT GGC AAG GGC TTC TCC T 239 and 59-
AGT GCT CAA GAT GGC CCG CTC CC 239; GAPDH, 59-
GCA GCC TCC CGC TTC GCT CT 239 and 59- TGG TGA
CCA GGC GCC CAA TAC G - 39. Real-time RT-PCR was
carried out using Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster city, CA, USA) in an ABI Prism 7500 sequence
detector (Applied Biosystems, Foster city, CA, USA) in accordance
with the manufacturer’s protocol. GAPDH was used to standard-
ize cDNA input levels.
Immunohistochemistry
After deparaffination and rehydration, the slides were subjected
to 0.3% hydrogen peroxide for 30 min to quench endogenous
peroxidase activity. Blocking was done with 10% normal donkey
serum (NDS) and 1% BSA in 1XPBS. Then the slides were
incubated overnight at 4uC in blocking buffer containing following
primary antibody; anti-human LAP2 (1:200, BD Biosciences, San
Jose, CA, USA), anti-STAT3 (1:100, Cell Signaling, Beverly,
MA,USA), anti-IL6 (1:100, ABCAM, Cambridge, UK) or anti-
MARCKS (1:50, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) antibody. Secondary antibody (horseradish peroxidase-
conjugated) binding was done at a 1:200 dilution in blocking
buffer for 2 h at RT. Detection was performed with HRP (Vector
Laboratories) by using the DAB substrate kit (Vector Laborato-
ries). Counterstaining was done for 1 min with hematoxylin
staining buffer (Sigma–Aldrich, St. Louis, MO).
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Two, three or five days following transfection with siRNA, we
added 10 ml of pre-mixed water-soluble tetrazolium salt-1 (WST-
1, Roche, Indianapolis, IN, USA) cell proliferation reagent into
each well. These cells were incubated for two hr in the incubator.
Cell viability was measured by absorbance at 450 nm using an
ELISA reader (TECAN, Mannedorf, Switzerland).
Figure 1. LAP2 is overexpressed in diverse digestive tract cancers. (A) Immunohistochemical staining showed overexpression of LAP2 in
diverse digestive tract cancers including pancreas, liver, stomach and bile duct cancers. Note overexpression of LAP2 in metastatic cancer cells. Scale
bar, 200 mm. (B) Overexpression of LAP2b in gastric cancer tissues was examined by real-time PCR using specific primers for the b-isoform. GAPDH
was used to normalize all data.
doi:10.1371/journal.pone.0039482.g001
Figure 2. Role of LAP2b in the proliferation of cancer cells. Western blotting (A, B) and real-time PCR (C, D) were used to determine the
efficiency of knockdown (A, C) or overexpression (B, D) of LAP2b in SNU638 or PANC1 cells. Data are the means6SD of three independent
experiments (*P,0.01, Student’s t-test). (E) Effect of LAP2b knockdown on proliferation of cancer cells. WST-1 assay was used to measure proliferation
of cancer cells in the presence of 10% FBS. Five days after transfection with by 100 nM LAP2b siRNA or 100 nM scrambled (SCR) siRNA, WST-1
proliferation assay was performed. (F) Effect of LAP2b overexpression on proliferation of cancer cells. WST-1 assay was conducted in SNU638 or
PANC1 cells overexpressing LAP2b gene or control vector. Data are the means6SD of three independent experiments in quintuplicate (*P,0.01,
Student’s t-test).
doi:10.1371/journal.pone.0039482.g002
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Migration of cancer cells was measured in a Boyden chamber.
Approximately 5610
4 cells in 0.05 ml of serum-free RPMI1640
medium were seeded to the well membrane–coated with Type I
collagen. To remove effects of proliferation, mitomycin C
(0.01 mg/ml, Sigma, USA) was added. Cells were allowed to
migrate for four or six hrs. Membranes were fixed and stained
using Diff-quik solution (Sysmex, Kobe, Japan) for one min and
washed with distilled water. Cell number in 10 randomly chosen
fields was determined using a light microscope. Experiments were
performed in triplicate and repeated thrice.
Wound Healing Assay
The cell monolayer was scratched with a yellow pipet tip and
migration of cells to the wounded area was observed under an
inverted microscope. To remove effects of proliferation, mitomy-
cin C (0.01 mg/ml, Sigma, USA) was added. Images were taken at
the indicated times. Measurements were taken from five individual
microscopic fields in each experiment, and the representative data
from three experiments are presented.
Matrigel Invasion Assay
The ability of cancer cells to invade was determined using
24-well BioCoatTM MatrigelTM chamber inserts (BD Bios-
ciences, San Jose, CA, USA). The inner insert of the invasion
chambers were coated with 0.5 mg/ml growth factor-reduced
Matrigel (BD Biosciences, San Jose, CA, USA) and the outer
insert by 0.5 mg/ml of fibronectin (Sigma-Aldrich, St. Louis,
MO, USA). Cells were seeded into inserts at a density of 5610
4
per insert in serum-free medium and then transferred to wells
filled with the culture medium containing 10% FBS or 100 ng/
ml EGF as a chemoattractant. To remove effects of pro-
liferation, mitomycin C (0.01 mg/ml, Sigma, USA) was added.
After 24 (10% FBS) or 52 hrs (100 ng/ml EGF) of incubation,
non-invading cells on the top of the membrane were removed
by scraping. Invaded cells on the bottom of the membrane were
fixed, followed by staining with Diff-quik solution. Experiments
were performed in triplicate, and at least 10 fields were counted
in each experiment.
Liver Metastasis Xenograft Model
The ability of the transfectants to metastasize to the liver was
evaluated by slowly injecting cells (5610
6/0.05 ml) into the
spleen of nude mice via a 27-gauge needle (NK4 group, mock
group; n=5/group). For pathological studies, all mice were
killed at 5 weeks and livers were isolated, fixed in 10% neutral -
buffered formalin, and embedded in paraffin. Sections were
stained with hematoxylin and eosin. This study was carried out
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health. The Pusan National University Institutional
Animal Care and Use Committee (PNUIACUC) approved the
experimental procedures (Permit Number: PNU-2010-00083).
cDNA Microarray
Total RNA was extracted from SNU638-LAP2 and SNU638
mock cells using RNeasy Mini kit (Qiagen, Valencia, CA, USA) in
accordance with the manufacturer’s protocol. Quantified RNA
was then used for microarray analysis on Human HT-12_v4_Bead
chips (Illumina Inc., San Diego, CA, USA). Total RNA samples
were labeled using the Illumina TotalPrep RNA Amplification Kit
(Ambion, Applied Biosystem, CA, USA) for cDNA synthesis and
in vitro transcription. Single-stranded RNA (cRNA) was generated
and labeled by incorporating biotin-NTP (Ambion). A total of
0.5 mg of biotin-labeled cRNA were hybridized at 58uC for 16 h
to Illumina’s Human HT-12_v4_BeadChip (Illumina). The
hybridized biotinylated cRNA was detected with streptavidin-
Cy3 and quantified using a BeadArray Reader Scanner (Illumina)
according to the manufacturer’s instructions. Array data were
processed and analyzed by Illumina BeadStudio version 3.0
software (Illumina). Scanned data were normalized by the
quantile-quantile normalization method and log-transformed (by
base two). All data are MIAME compliant and the raw data were
submitted to the public repository (NCBI’s GEO Accession
Number: GSE31450).
Data Analysis
All data are presented as means6SD. The difference between
the mean values of two groups was evaluated using the Student’s t-
test (unpaired). For comparison of more than 3 groups, a one-way
analysis of variance (ANOVA), followed by Tukey’s multiple
comparisons were used. *Indicates a P value of ,0.05, which was
considered statistically significant.
Results
LAP2 is Widely Overexpressed in Diverse Digestive Tract
Cancers
To examine expression patterns of LAP2 in digestive track
cancers including stomach, pancreas, liver, and bile duct cancer,
we carried out immunohistochemistry using patient tissues (n=15
per each cancer type). LAP2 protein was widely overexpressed in
the cancerous area of tissues compared to non-cancerous areas
(Fig. 1A, 47% in stomach cancer, 27% in pancreas cancer, 30% in
liver cancer, 40% in bile duct cancer). Notably, expression of
LAP2 was observed in metastatic cancer cells of patients’ tissues.
Because LAP2 has numerous isoforms, we focused on LAP2b.T o
confirm the results of immunohistochemistsry, we performed real-
time PCR using LAP2b-specific primers in gastric cancer tissues.
Although all tested tissues did not overexpress LAP2b, it was
overexpressed in 13 cases (total 24 cases, Fig. 1B).
Roles of LAP2b in Proliferation, Migration, and Invasion of
Cancer Cells
To examine roles of LAP2b in carcinogenesis, we knocked-
down or overexpressed LAP2b using siRNA or cDNA, re-
spectively. We checked the efficiency of the modulation of
Figure 3. LAP2b regulates migration of diverse digestive tract cancers cells. Boyden chamber assay (A-G) and wound healing assay (H,
SNU638 cells) were used to measure migration of cancer cells. LAP2b siRNA significantly inhibited FBS- or EGF-induced migration compared to SCR
siRNA in SNU638 (A, C), PANC1 (A, D) or other digestive tract cancer cells (G). Overexpression of LAP2b in SNU638 (B, E) or PANC1 (B, F) cells
significantly increased migration compared to the control vector (B, E, F). EGF (100 ng/ml) or 10% FBS was used to induce chemotaxis. Mitomycin C
(0.01 mg/ml) was added to remove effects of proliferation. Two days after transfection with 100 nM LAP2b siRNA or 100 nM scrambled (SCR) siRNA,
both migration assays were performed. Four or six hours later after addition of EGF or FBS into Boyden chamber assay, cells were fixed. After a scratch
in wound healing assay, migrated cells were fixed at the indicated times. Representative staining of migrated cells was presented (A, B). Migrated cells
were counted and the data are presented as graphs (C-G). Data are the means6SD of three independent experiments in triplicate (C-G, *P,0.01,
Student’s t-test).
doi:10.1371/journal.pone.0039482.g003
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LAP2b siRNA (100 nM) decreased the mRNA level of LAP2b
in SNU638 or PANC1 cells compared to SCR siRNA by 42%
or 61%. Overexpression of LAP2b by cDNA transfection
increased the mRNA level of LAP2b in SNU638 or PANC1
cells (clone#6) compared to the control vector by 1.7 or 19.6
fold respectively.
Next, we examined the role of LAP2b in proliferation of cancer
cells.FivedaysaftertransfectionwithSCRorLAP2bsiRNA,WST-1
proliferation assay was carried out. Knockdown of LAP2b did not
Figure 4. LAP2b regulates invasion of gastric and pancreatic cancer cells. Matrigel invasion assay was used to measure invasion of cancer
cells. Knockdown of LAP2b significantly inhibited FBS- and EGF-induced invasion compared to SCR siRNA in SNU638 (A, C) or PANC1 (A, D) cells.
Overexpression of LAP2b in SNU638 (B, E) or PANC1 (B, F) cells significantly increased invasion compared to the control vector. EGF (100 ng/ml) or
10% FBS was used to induce invasion. Mitomycin C (0.01 mg/ml) was added to remove effects of proliferation. Two days after transfection with
100 nM LAP2b siRNA or 100 nM scrambled (SCR) siRNA, the invasion assays were performed. Representative staining of invaded cells was presented
(A, B). Invaded cells were counted and the data are presented as graphs (C-F). Data are the means6SD of three independent experiments in triplicate
(C-F, *P,0.01, Student’s t-test).
doi:10.1371/journal.pone.0039482.g004
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cancercells(Fig.2E).LAP2bsiRNAinhibitedproliferationofMIA-
PaCa2andPANC1pancreaticcancercellscomparedtoSCRsiRNA
by 74% and 46% respectively (Fig. 2E). We observed similar results
whenweperformedWST-1proliferationassaytwoorthreedaysafter
the transfection. Overexpression of LAP2b in SNU638 or PANC1
cells slightly affectedproliferation (Fig. 2F).
To determine the role of LAP2b in migration of cancer cells, we
conducted studies using a Boyden chamber assay. In all tested
cancer cells, knockdown of LAP2b inhibited migration of cancer
cells (Fig. 3). For example, LAP2b siRNA inhibited FBS- or EGF-
induced migration of SNU638 cells compared to SCR siRNA by
47% and 70% respectively (Fig. 3A, & 3C). In constrast,
overexpression of LAP2b increased FBS- and EGF-induced
migration of SNU638 cells compared to mock cells by 145%
and 387% respectively (Fig. 3B & 3E). Similar results were
obtained in LAP2b- overexpressing PANC1 cells (Fig. 3B & 3F).
This effect on migration of cancer cells was further confirmed by
a wound healing assay in SNU638 cells (Fig. 3H). These results led
us to examine the role of LAP2b in the invasion of cancer cells. In
a Matrigel invasion assay, LAP2b siRNA inhibited FBS- and
EGF-induced invasion of SNU638 cells compared to SCR siRNA
by 93% and 47% respectively (Fig. 4A & 4C). Similar results were
obtained in PANC1 (Fig. 4A & 4D) or SNU216 (data not shown)
cells. In contrast, overexpression of LAP2b increased FBS- and
EGF-induced invasion of SNU638 cells compared to control
vector by 725% and 1,223% respectively (Fig. 4B & 4E). Similar
results were obtained in PANC1 (Fig. 4B & 4F) cells.
LAP2b Enhances Metastatic Efficacy of Gastric Cancer
Cells in a Liver Metastasis Xenograft Model
Regulation of the motility of cancer cells by LAP2b suggested
the possibility that LAP2b regulates metastasis of cancer cells in
vivo. To examine this possibility, we injected gastric cancer cells
into spleen of nude mice and then observed metastasis in the liver.
Interestingly, overexpression of LAP2b increased the efficiency
and the size of liver metastasis (Fig. 5) and mortality of tested mice.
67% of mice injected with gastric cancer cells overexpressing
LAP2b died 8 weeks later after the injection, while all control mice
injected with gastric cancer cells expressing control vector
survived. In the histological examination of xenograft tissues, we
confirmed overexpression of LAP2b in the xenograft derived from
mice injected with LAP2b-overexpressing cells (Fig. 5).
LAP2b-induced Changes in mRNA Expression
To reveal the underlying mechanism of LAP2b-regulated
motility, we performed a cDNA microarray (NCBI’s GEO
Figure 5. LAP2b enhances metastatic efficiency in a xenograft
model. Gastric cancer cells overexpressing LAP2b gene or control
vector were injected into spleen and metastasis to liver was examined 5
weeks later. Metastatic tumor regions were indicated by dotted circles.
Representative immunostainings with anti-LAP2, anti-IL6, anti-STAT3,
and anti-MARCKS antibodies, and H&E stainings in a liver metastasis are
presented. Asterisk indicates tumor lesions. Scale bar, 50 mm.
doi:10.1371/journal.pone.0039482.g005
Table 1. LAP2b-induced change in gene expression.
UP DOWN
Probe ID Target ID FC Probe ID Target ID FC
4830541 HBE1 13.43 1780482 CACHD1 0.78
430446 KRT81 10.02 4810128 PHLDA2 0.67
2630240 SPINK6 9.22 870338 EGR1 0.65
6590132 IGFBP3 5.71 2570300 IFI44 0.51
2600133 ALPP 4.11 4640086 FOXQ1 0.50
1980132 SPINK6 4.04 4900561 PSG1 0.49
5570768 HOXA11AS 3.15 2060040 ADORA2B 0.48
7210192 ADA 2.90 1580435 TGM2 0.46
610437 CD24 2.49 2970154 KLK6 0.45
2940746 NNMT 2.24 6940475 AKAP12 0.44
730739 TCEAL3 2.05 2370450 ASPH 0.44
3140619 OR51B5 2.03 5860039 CALB2 0.44
6060484 MARCKS 1.94 670041 AKAP12 0.44
510097 HOXA10 1.85 1580246 LOC399959 0.40
4150014 CEACAM1 1.81 2060477 AGPAT9 0.34
4040576 IL6 1.69 6330270 GPC4 0.30
5090619 STAT3 1.50 3190112 SERPINB1 0.26
FC, fold change.
doi:10.1371/journal.pone.0039482.t001
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LAP2b was overexpressed in the stable cell line about 1.7 fold,
those of many genes were changed by the overexpression (Fig. 2
& Table 1). Among the significantly changed genes by LAP2b,
we focused on myristoylated alanine-rich C kinase substrate
(MARCKS), signal transducer and activator of transcription3
(STAT3) and interleukin6 (IL6) because these genes have been
reported to regulate motility of cells. Real-time PCR for each
gene confirmed significant changes in mRNA levels of each gene
(Fig. 6). Overexpression of LAP2b increased the mRNA levels of
MARCKS and IL6 compared to control vector by 193% and
79% respectively (Fig. 6). Moreover, increased expressions of
MARCKS, IL6 and STAT3 were observed in the xenograft
derived from mice injected with LAP2b-overexpressing cells
(Fig. 5).
Discussion
LAP2, one of LEM domain proteins, has been mainly described
to play a structural role in the nuclear membrane and to be
involved in several genetic disorders. However, here we present for
the first time its expression and roles in diverse digestive tract
cancers. In particular, we found that LAP2b can control motility
of cancer cells as well as contribute to metastasis of cancer cells.
Metastasis of cancer cells greatly affects the prognosis of cancer
patients. Several results in the present study support that LAP2b
regulates the motility and metastasis of cancer cells. In vitro
experiments in the Boyden chamber, wound healing and Matrigel
invasion assays, showed that knockdown decreased while over-
expression of LAP2b increased the migration and invasion of
cancer cells (Fig. 3 & 4). Moreover, in the xenograft model, LAP2b
enhanced metastasis of cancer cells (Fig. 5). Although control
vector-transfected cells caused metastasis in the xenograft model,
the effect was quite inefficient and slow. In contrast, LAP2b-
overexpressed cells showed a more aggressive behavior in the
xenograft. Furthermore, we found overexpression of LAP2 in
metastatic cancer cells of tissues from patients (Fig. 1).
How can LAP2b contribute to motility and metastasis of cancer
cells? We found several genes which were induced by LAP2b in
the cDNA microarray analysis (Table 1), which was further
confirmed by real-time PCR (Fig. 6) and immunohistochemistry in
xenograft (Fig. 5). One of them, MARCKS, is responsible for the
binding and cross-linking of actin filaments directly to the
membrane [24]. Overexpression of MARCKS has been found
in various cancers including hepatocellular carcinoma [25],
pancreatic cancer [26], glioblastoma [27] and cholangiocarcinoma
[28]. Moreover, MARCKS plays a critical role in EGFR-induced
invasion of glioblastoma cells [29]. Many other studies have been
shown the involvement of MARCKS in cellular motility [30].
Another candidate gene which mediates LAP2b-induced
motility is IL-6, which is primarily produced during acute and
chronic inflammation. Cancer cells that are exposed to IL-6 or
secrete the cytokine as an autocrine factor show increased
invasiveness [31,32,33]. Moreover, the inactivation of gp130,
a transducer of IL-6 signaling, reduced the aggressiveness of breast
cancer cells in vivo [34]. Several IL-6 signaling pathway-related
genes including STAT3 are also associated with migration and
invasion of cancer cells [35,36,37]. IL-6 is widely expressed in
many solid cancers including prostate [38], breast [39], lung [40]
cancer, and glioblastoma [41].
How can LAP2b regulate gene expression? LEM-domain
proteins have been shown to be able to regulate gene expression
by sequestering transcriptional regulators to the nuclear lamina.
MAN1 binds to receptor-regulated R-Smads and antagonizes
signaling by transforming growth factor b (TGFb), activin and
bone morphogenic protein (BMP) [42]. MAN1 deficiency leads to
embryonic vascular remodeling defects in mice and bone de-
velopment in humans [16,43]. Another example is emerin binding
to b–catenin, a downstream target of Wnt signaling, which
promotes its exit from the nucleus [44]. Emerin deficiency leads to
nuclear accumulation of b-catenin. LAP2b has been shown to
interact with HDAC3 and regulate activity of E2F, p53 and NF-
kB transcription factors [5,45]. In future studies, how LAP2b can
regulate MARCKS or IL-6 expression warrants further in-
vestigation.
The involvement of LAP2b in replication was suggested by
a study in which truncated LAP2b altered DNA replication
efficiency [18]. The regulation of DNA replication by LAP2b has
been suggested to be mediated by two possible pathways. LAP2b
can reduce the activity of E2F complex alone or with germ cell less
(GCL) [46]. The other pathway is through interaction with HA95
during the G1 phase of the cell cycle [12]. This interaction with
HA95 contributes to the stability of the prereplication complexes.
In the present study, knockdown of LAP2b did not affect
proliferation of most digestive tract cancer cells except pancreatic
cancer cells (Fig. 2). Moreover, overexpression of LAP2b did not
cause significant change in proliferation (Fig. 2), suggesting the
regulation of proliferation by LAP2b in digestive tract cancer cells
is not so critical.
Widespread overexpression of LAP2 in various digestive tract
cancers is described for the first time in the present study (Fig. 1).
Expression of LAP2b has been described in various normal tissues
including skin, thymus, lung, testis and ovary. However, its
expression in normal gastrointestinal tract was rarely detected
[47]. Overexpression of LAP2b was reported in various hemato-
logical malignant cells and neuroblastoma cells [17,48]. Moreover,
LAP2a is overexpressed in various solid cancers including larynx,
lung, stomach, breast and colon cancer [19]. Interestingly, the
Figure 6. LAP2b-induced gene expression. Gene expression
between gastric cancer cells overepxressing LAP2b gene or control
vectors were compared by cDNA microarray. Real-time PCR was used to
confirm the LAP2b-induced change in gene expression of MARCKS,
STAT3 and IL-6 in SNU638 cells. The data are plotted as fold changes
compared with mock cells. Data are the means6SD of three
independent experiments in quintuplicate (*P,0.01, Student’s t-test).
doi:10.1371/journal.pone.0039482.g006
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factor, E2F [19].
In the present study, we found that LAP2 is widely over-
expressed in digestive tract cancer cells and plays critical roles in
motility of cancer cells. Although the detailed underlying
mechanism for regulation of motility needs to be examined in
future studies, these data suggest that LAP2b may be a possible
target for therapeutics and diagnostics.
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